VEGFA and ovarian carcinoma: Based on pre-clinical findings linking perivascular status to sensitivity to e.g. VEGF-targeting agents [34, 49], it appears that further exploration of perivascular makers should be carried out to evaluate their potential role as predictive markers for new anti-angiogenic drugs in the treatment of ovarian cancer.